Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
Company's REZPEG demonstrated durable efficacy, with SALT Score =20 rates rising to 27.6% at 52 weeks in severe-to-very-severe AA patients. Multiple near-term catalysts include 2026–2027 data readouts for REZPEG in AA, AD, and new-onset Type 1 Diabetes, supporting further upside potential. Recent financings provide extended runway beyond prior 12-month cash outlook, enabling NKTR to advance pivotal programs and capitalize on large autoimmune markets. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Nuttawan Jayawan/iStock via Getty Images The last time I spoke about Nektar Therapeutics NKTR ) it was with a Seeking Alpha article entitled " Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC ." With More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Al
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Announces Proposed Public Offering [TheStreet.com]TheStreet.com
- Nektar Therapeutics Announces Proposed Public OfferingPR Newswire
- NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & KorsinskyGlobeNewswire
- Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript [Seeking Alpha]Seeking Alpha
- Nektar Therapeutics (NKTR) had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a "buy" rating on the stock.MarketBeat
NKTR
Earnings
- 3/12/26 - Beat
NKTR
Sec Filings
- 4/20/26 - Form 424B5
- 4/20/26 - Form 8-K
- 4/20/26 - Form 8-K
- NKTR's page on the SEC website